In addition to in vitro experiments, analysis involving R/R B-cell lymphoma patients treated with tandem CD19/20 CAR T-cell treatment revealed poorer response and survival when patients had low NOXA protein levels in tumor samples (Fig. 6k). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.